Horizon Therapeutics plc Confirms Preliminary Discussions Regarding Potential Offer

Jefferies sees up to 90% chance Horizon Therapeutics (HZNP) gets acquired, with $125 base case

Jefferies analyst Akash Tewari was the latest Wall Street analyst to weigh in on the takeover prospects of Horizon Therapeutics (NASDAQ: HZNP) after the company announced Tuesday that it is in preliminary talks with three large pharmaceutical companies about a potential buyout.

Tewari is positive on the prospects of a deal and sees one happening in the $25-$30 billion range, which he also said does not bake in Tepezza peak sales of $4 billion.

The analyst said the... More

'Compelling value' in Viridian Therapeutics following Horizon Therapeutics acquisition talks

Shares of Viridian Therapeutics (NASDAQ: VRDN) jumped Wednesday on the back of news on Tuesday evening that Horizon Therapeutics (NASDAQ: HZNP) is in "highly preliminary discussions" with three large pharmaceutical companies.

Horizon Therapeutics shares are up more than 27% during Wednesday's session, while Viridian Therapeutics has also reacted to the news, currently up over 13%.

Within Horizon's portfolio of... More

Horizon Therapeutics seen worth up to $140/share in takeover

Several Wall Street analysts put pencil to paper after Horizon Therapeutics (NASDAQ: HZNP) said Tuesday evening that it was in "highly preliminary" takeover talks with Amgen Inc. (NYSE: AMGN), Janssen Global Services, LLC (NYSE: JNJ), and Sanofi (NYSE: SNY). A deal price as high as $140 per share was the high watermark discussed by at least two analysts.

Cowen analyst Ken Cacciatore said that given their belief that Tepezza's previous pause was... More

Horizon Therapeutics (HZNP) jumps after confirming takeover talks with 3 parties

Shares of Horizon Therapeutics (NASDAQ: HZNP) surged over 30% after-hours Tuesday after the company confirmed that it was in "highly preliminary" takeover talks with Amgen Inc. (NYSE: AMGN), Janssen Global Services, LLC (NYSE:... More

Horizon Therapeutics (HZNP) resumes trading, up 39%

Horizon Therapeutics (NASDAQ: HZNP) resumes trading, up 39%